131 related articles for article (PubMed ID: 33232790)
1. Letter to the editor regarding "Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma".
Lin J
Cancer Lett; 2021 Feb; 499():1. PubMed ID: 33232790
[No Abstract] [Full Text] [Related]
2. Response to the Letter to the editor regarding "Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma" by Jiong Lin.
Santofimia-Castaño P; Lan W; Xia Y; Zhou Z; Huang C; Barea D; Cervello M; Giannitrapani L; Montalto G; Peng L; Iovanna J
Cancer Lett; 2021 Mar; 500():161-162. PubMed ID: 33290870
[No Abstract] [Full Text] [Related]
3. Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma.
Lan W; Santofimia-Castaño P; Xia Y; Zhou Z; Huang C; Fraunhoffer N; Barea D; Cervello M; Giannitrapani L; Montalto G; Peng L; Iovanna J
Cancer Lett; 2020 Aug; 486():8-17. PubMed ID: 32446862
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cells in hepatocellular carcinomas.
Das P; Gupta SD
Indian J Med Res; 2015 Oct; 142(4):362-5. PubMed ID: 26609026
[No Abstract] [Full Text] [Related]
5. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma.
Huang CC; Wu MC; Xu GW; Li DZ; Cheng H; Tu ZX; Jiang HQ; Gu JR
J Natl Cancer Inst; 1992 Feb; 84(4):262-4. PubMed ID: 1346405
[No Abstract] [Full Text] [Related]
6. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma.
Santofimia-Castaño P; Xia Y; Peng L; Velázquez-Campoy A; Abián O; Lan W; Lomberk G; Urrutia R; Rizzuti B; Soubeyran P; Neira JL; Iovanna J
Cells; 2019 Nov; 8(11):. PubMed ID: 31744261
[TBL] [Abstract][Full Text] [Related]
7. NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.
Emma MR; Iovanna JL; Bachvarov D; Puleio R; Loria GR; Augello G; Candido S; Libra M; Gulino A; Cancila V; McCubrey JA; Montalto G; Cervello M
Cell Death Dis; 2016 Jun; 7(6):e2269. PubMed ID: 27336713
[TBL] [Abstract][Full Text] [Related]
8. ZZW-115-dependent inhibition of NUPR1 nuclear translocation sensitizes cancer cells to genotoxic agents.
Lan W; Santofimia-Castaño P; Swayden M; Xia Y; Zhou Z; Audebert S; Camoin L; Huang C; Peng L; Jiménez-Alesanco A; Velázquez-Campoy A; Abián O; Lomberk G; Urrutia R; Rizzuti B; Geli V; Soubeyran P; Neira JL; Iovanna J
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32780723
[TBL] [Abstract][Full Text] [Related]
9. Identification of a mitochondrial defect gene signature reveals NUPR1 as a key regulator of liver cancer progression.
Lee YK; Jee BA; Kwon SM; Yoon YS; Xu WG; Wang HJ; Wang XW; Thorgeirsson SS; Lee JS; Woo HG; Yoon G
Hepatology; 2015 Oct; 62(4):1174-89. PubMed ID: 26173068
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance in hepatic cancer stem cells: the emerging role of miRNAs.
Sukowati CH; Anfuso B; Pascut D; Tiribelli C
Expert Rev Gastroenterol Hepatol; 2015 Jun; 9(6):723-5. PubMed ID: 25920931
[TBL] [Abstract][Full Text] [Related]
11. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
12. Targeting chemokines as a therapeutic option for hepatocellular carcinoma: a reality or just a fantasy?
Yu J
J Gastroenterol Hepatol; 2007 May; 22(5):611-2. PubMed ID: 17444845
[No Abstract] [Full Text] [Related]
13. P-glycoprotein expression in hepatocellular carcinoma.
Isshiki K; Nakao A; Ito M; Hamaguchi M; Takagi H
J Surg Oncol; 1993 Jan; 52(1):21-5. PubMed ID: 8095077
[TBL] [Abstract][Full Text] [Related]
14. Toward construction of a transcript profile database predictive of chemical toxicity.
Corton JC; Stauber AJ
Toxicol Sci; 2000 Dec; 58(2):217-9. PubMed ID: 11099633
[No Abstract] [Full Text] [Related]
15. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
16. Pituitary tumor transforming gene 1 in the liver.
Grizzi F; Franceschini B; Musardo S; Frezza EE; Cobos E; Chiriva-Internati M
Hepatology; 2006 Dec; 44(6):1701-2. PubMed ID: 17133495
[No Abstract] [Full Text] [Related]
17. [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy].
Marquardt JU; Galle PR; Teufel A
Dtsch Med Wochenschr; 2012 Apr; 137(16):855-60. PubMed ID: 22495921
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus X promotes hepatocellular carcinoma development via nuclear protein 1 pathway.
Bak Y; Shin HJ; Bak Is; Yoon DY; Yu DY
Biochem Biophys Res Commun; 2015 Oct; 466(4):676-81. PubMed ID: 26392315
[TBL] [Abstract][Full Text] [Related]
19. Long Non-Coding RNAs as Mediators of Tumor Microenvironment and Liver Cancer Cell Communication.
Lin YH; Wu MH; Yeh CT; Lin KH
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30477236
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?
Giordano S; Columbano A
Hepatology; 2013 Feb; 57(2):840-7. PubMed ID: 23081718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
